By Nigam Arora & Dr. Natasha Arora
We have previously shared with you in a Morning Capsule that India would be the main beneficiary of China’s crackdown on its tech stocks. Now we see the evidence that it is actually happening – some of the foreign money intended for China is now flowing into India.
Please click here for a chart of India ETF EPI. As the chart shows, technically Indian stocks have broken out to an all-time high.
For very long-term investors, India represents one of the best opportunities. However, at times, Indian stocks can be very volatile. It is important to pay attention to the buy zone and scale in. Please see Trade Management Guidelines about scaling in.
Further, similar to U. S. stocks, Indian stocks are also driven by easy money. Just like the Fed in the U. S. will have difficulty continuing with its present easy money policy forever, the Reserve Bank of India is in the same situation.
Buy Zone
The buy zone for EPI is 🔒 (To see the locked content, please take a 30 day free trial. EPI is trading at $35.33 as of this writing in the premarket.
Ratings
The short-term rating for India is Neutral because of weak seasonality ahead. On a dip into the buy zone, the short-term rating will become ‘Buy.’
The medium-term rating remains Mild Buy and long-term rating remains Strong Buy. Please see Trade Management Guidelines for the definition of time frames.
To take a free 30-day trial to paid services to gain access to more opportunities, please click here.
This post was just published on ZYX Emerging Markets ETF Alert.
Markets can generate substantial wealth for knowledgeable investors. NOW YOU TOO CAN ALSO SPECTACULARLY SUCCEED AT MEETING YOUR GOALS WITH THE HELP OF THE ARORA REPORT. You are receiving less than 2% of the content from our paid services. …TO RECEIVE REMAINING 98% INCLUDING MANY ATTRACTIVE INVESTMENT OPPORTUNITIES, TAKE A FREE
TRIAL TO PAID SERVICES.
Please click here to take advantage of a FREE 30 day trial.
Nigam Arora
Nigam Arora is known for his accurate stock market calls. Nigam is a distinguished master of the macro. He is a popular columnist with over 100 million page views, an engineer, and nuclear physicist by background. Nigam has founded two Inc. 500 fastest growing companies and has been involved in over 50 entrepreneurial ventures. He is the developer of Theory ZYX of Successful Change Management and is the author of the book on Theory ZYX, as well as the developer of the ZYX Change Method for Investing.
Dr. Natasha Arora
Dr. Natasha Arora has significant expertise in investment analysis especially biotech, healthcare, and technology. Natasha is a graduate of Harvard Medical School followed by a postdoc at MIT. She has published several peer reviewed research papers in top science journals.
